JP5607746B2 - 固体のガドベネートジメグルミン錯体の製造方法 - Google Patents
固体のガドベネートジメグルミン錯体の製造方法 Download PDFInfo
- Publication number
- JP5607746B2 JP5607746B2 JP2012539358A JP2012539358A JP5607746B2 JP 5607746 B2 JP5607746 B2 JP 5607746B2 JP 2012539358 A JP2012539358 A JP 2012539358A JP 2012539358 A JP2012539358 A JP 2012539358A JP 5607746 B2 JP5607746 B2 JP 5607746B2
- Authority
- JP
- Japan
- Prior art keywords
- gadobenate dimeglumine
- solid
- water
- liquid composition
- bopta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000007787 solid Substances 0.000 title claims description 62
- OCDAWJYGVOLXGZ-VPVMAENOSA-K gadobenate dimeglumine Chemical compound [Gd+3].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)C(C([O-])=O)COCC1=CC=CC=C1 OCDAWJYGVOLXGZ-VPVMAENOSA-K 0.000 title claims description 49
- 229940096814 gadobenate dimeglumine Drugs 0.000 title claims description 48
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 238000000034 method Methods 0.000 claims description 53
- 239000000203 mixture Substances 0.000 claims description 31
- 238000001694 spray drying Methods 0.000 claims description 28
- 239000007788 liquid Substances 0.000 claims description 27
- 239000007864 aqueous solution Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 20
- 239000007921 spray Substances 0.000 claims description 11
- 239000012530 fluid Substances 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 10
- 239000008365 aqueous carrier Substances 0.000 claims description 4
- 239000008215 water for injection Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 239000002872 contrast media Substances 0.000 description 8
- VJYFKVYYMZPMAB-UHFFFAOYSA-N ethoprophos Chemical compound CCCSP(=O)(OCC)SCCC VJYFKVYYMZPMAB-UHFFFAOYSA-N 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- 238000002955 isolation Methods 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- MXZROTBGJUUXID-UHFFFAOYSA-K gadobenic acid Chemical compound [H+].[H+].[Gd+3].[O-]C(=O)CN(CC([O-])=O)CCN(CC(=O)[O-])CCN(CC([O-])=O)C(C([O-])=O)COCC1=CC=CC=C1 MXZROTBGJUUXID-UHFFFAOYSA-K 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000002059 diagnostic imaging Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000002616 MRI contrast agent Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000005298 paramagnetic effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000012265 solid product Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229910052688 Gadolinium Inorganic materials 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- -1 gadobenate dimeglumine compound Chemical class 0.000 description 2
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003791 organic solvent mixture Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- GOBUYIKQNYUPDZ-ZDUSSCGKSA-N (2S)-2-[2-(2-aminoethylamino)ethoxy-benzylamino]-3-hydroxypropanoic acid Chemical compound NCCNCCON([C@@H](CO)C(=O)O)CC1=CC=CC=C1 GOBUYIKQNYUPDZ-ZDUSSCGKSA-N 0.000 description 1
- NDQQRRVKUBPTHQ-QBIQUQHTSA-N (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO NDQQRRVKUBPTHQ-QBIQUQHTSA-N 0.000 description 1
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- 0 CCCCC*CN(CCN(C*)CCN(C*C)C(COCc1ccccc1)*C)C*C Chemical compound CCCCC*CN(CCN(C*)CCN(C*C)C(COCc1ccccc1)*C)C*C 0.000 description 1
- XLXPHOYILHPROC-VKHMYHEASA-O C[NH2+]C[C@@H](C(O)O)O Chemical compound C[NH2+]C[C@@H](C(O)O)O XLXPHOYILHPROC-VKHMYHEASA-O 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- IQUHNCOJRJBMSU-UHFFFAOYSA-N H3HP-DO3A Chemical compound CC(O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 IQUHNCOJRJBMSU-UHFFFAOYSA-N 0.000 description 1
- 238000003109 Karl Fischer titration Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- MXZROTBGJUUXID-UHFFFAOYSA-I [Gd+3].[O-]C(=O)CN(CC([O-])=O)CCN(CC(=O)[O-])CCN(CC([O-])=O)C(C([O-])=O)COCC1=CC=CC=C1 Chemical compound [Gd+3].[O-]C(=O)CN(CC([O-])=O)CCN(CC(=O)[O-])CCN(CC([O-])=O)C(C([O-])=O)COCC1=CC=CC=C1 MXZROTBGJUUXID-UHFFFAOYSA-I 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012539 chromatography resin Substances 0.000 description 1
- 239000012084 conversion product Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000010981 drying operation Methods 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 229910001867 inorganic solvent Inorganic materials 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000013386 optimize process Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 239000004552 water soluble powder Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1887—Agglomerates, clusters, i.e. more than one (super)(para)magnetic microparticle or nanoparticle are aggregated or entrapped in the same maxtrix
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/38—Separation; Purification; Stabilisation; Use of additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C67/00—Shaping techniques not covered by groups B29C39/00 - B29C65/00, B29C70/00 or B29C73/00
- B29C67/24—Shaping techniques not covered by groups B29C39/00 - B29C65/00, B29C70/00 or B29C73/00 characterised by the choice of material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/10—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/38—Separation; Purification; Stabilisation; Use of additives
- C07C227/40—Separation; Purification
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Mechanical Engineering (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
i)微粒子化工程、
ii)選択した温度の並流乾燥ガスを用いることによりスプレー乾燥チャンバー内での乾燥操作、および最後に
iii)そのように形成された粒子の回収工程
にかける。
実施例1:スプレー乾燥により得られる固体のガドベネートジメグルミン(式I)
用いたスプレー乾燥装置:
2つの流体ノズルを備えた並流LAB PLANT SD04スプレー乾燥機。
2つの流体ノズルまたは加圧ノズルを備えた並流MOBILE MINORTMパイロットプラント。
加圧ノズルを備えた並流SDサイズ12.5プラント。
ガドベネートジメグルミン、一般的スプレー乾燥手順
同時に、熱気流をチャンバー内に吹き込み噴霧した粒子を乾燥させた。
次に、そのようにして製造した粉末をサイクロンを介した回収により排気気流(exhausted)から分離した。
固体をチャンバーの底に位置する試料回収機に集めた。
種々の条件(実施例1a-g)を試験し、プロセス変数を最適化し、本発明のプロセスの信頼性を裏付けた。
実施例1a
T-注入口:160℃
T-排出口:87℃
供給速度:8 g/min
310gのガドベネートジメグルミンを白色粉末として得た(収率85%; KF 2.23%)。
実施例1b
T-注入口:160℃
T-排出口:88℃
供給速度:8.8 g/min
333gのガドベネートジメグルミンを白色粉末として得た(収率91%; KF 1.74%)。
実施例1c
T-注入口:160℃
T-排出口:88℃
供給速度:5.9 g/min
208gのガドベネートジメグルミンを白色粉末として得た(収率81.5%; KF 1.36%)。
実施例1d
T-注入口:195℃
T-排出口:95℃
供給速度:6.1 g/min
232gのガドベネートジメグルミンを白色粉末として得た(収率83.4%; KF 2.95%)。
実施例1e
T-注入口:190℃
T-排出口:100℃
供給速度:3.9 kg/h
406.1gのガドベネートジメグルミンを白色粉末として得た(収率97%; KF 2.6%)。
実施例1f
T-注入口:150℃
T-排出口:80℃
供給速度:3.0 kg/h
608.3gのガドベネートジメグルミンを白色粉末として得た(収率94%; KF 2.2%)。
実施例1g
T-注入口:170℃
T-排出口:100℃
供給速度:40.0 kg/h
75.6kgのガドベネートジメグルミンを白色粉末として得た(収率91%; KF 1.7%)。
実施例1a〜gに従って得られた粉末ガドベネートは上記説明に記載のように非常に短い時間枠で水性溶液に容易に溶解するだろう。
実施例2:比較実施例
比較実施例2a:水の蒸発による単離
残渣を25℃、真空下(1mmHg)でP2O5とともに乾燥し、その硬さのため回収および再溶解が困難なガラス状の硬い固体をえた。
比較実施例2b:凍結乾燥による単離
比較実施例2c:沈殿による単離
粘着性のゴム状固体をリアクター中で沈殿により得た。その回収は、該固体の好ましくない粘度のためやっかいで面倒であった。
比較実施例2d:沈殿による単離
白色ゴム状固体を沈殿により得たが、この場合、その回収は、該固体の好ましくない粘度のためやっかいで面倒であった。
実施例3:スプレー乾燥により得られた固体のBOPTAリガンド(式II)
2つの流体ノズルまたは加圧ノズルを取り付けた並流MOBILE MINORTMパイロットプラント。
BOPTAの一般的スプレー乾燥手順
BOPTAリガンドの水性懸濁液または溶液を、2つの流体ノズルを取り付けた並気流の、温度約45〜50℃のスプレー乾燥機に供給した。
実施例3a
T-注入口:160℃
T-排出口:73℃
供給速度:2400 g/h
121.5gのBOPTAを白色粉末として得た(収率94%;KF 1.5 %)。
実施例3b
T-注入口:140℃
T-排出口:72℃
供給速度:1750 g/h
93.8gのBOPTAを白色粉末として得た(収率72%;KF 1.9%)。
Claims (12)
- 該液体組成物が少なくとも0.2Mの濃度を有する請求項1記載の方法。
- 該濃度が0.45M〜0.55Mからなる請求項2記載の方法。
- 該液体組成物が水性溶液である請求項1〜3のいずれかに記載の方法。
- 該水性溶液が精製水溶液である請求項4記載の方法。
- スプレー乾燥機の注入口温度(T注入口)が140℃〜280℃からなり、排出口温度(T排出口)が70℃〜120℃からなる請求項1〜5のいずれかに記載の方法。
- 圧または2つの流体ノズルを用いて請求項1記載の液体組成物を微粒子化することを含む請求項1〜6のいずれかに記載の方法。
- 請求項1〜7のいずれかに記載の方法により得ることができる、水溶性固体粉末のガドベネートジメグルミン。
- 該粉末の粒子サイズが1μm〜200μmであることを特徴とする請求項8記載の水溶性固体粉末のガドベネートジメグルミン。
- 粒子サイズ20μm〜70μmであることを特徴とする請求項9に記載の水溶性固体粉末のガドベネートジメグルミン。
- スプレー乾燥された請求項8〜10のいずれかに記載の水溶性固体粉末のガドベネートジメグルミンを含む第1容器と、生理学的に許容される水性担体を含む第2容器を含む医薬キット。
- 該生理学的に許容される水性担体が注射用水である請求項11記載の医薬キット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09176713.7 | 2009-11-23 | ||
EP09176713A EP2327395A1 (en) | 2009-11-23 | 2009-11-23 | Process for the preparation of gadobenate dimeglumine complex in a solid form |
PCT/EP2010/067981 WO2011061341A1 (en) | 2009-11-23 | 2010-11-23 | Process for the preparation of gadobenate dimeglumine complex in a solid form |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013511497A JP2013511497A (ja) | 2013-04-04 |
JP5607746B2 true JP5607746B2 (ja) | 2014-10-15 |
Family
ID=42077873
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012539358A Active JP5607746B2 (ja) | 2009-11-23 | 2010-11-23 | 固体のガドベネートジメグルミン錯体の製造方法 |
Country Status (21)
Country | Link |
---|---|
US (2) | US20120232151A1 (ja) |
EP (2) | EP2327395A1 (ja) |
JP (1) | JP5607746B2 (ja) |
KR (2) | KR101624504B1 (ja) |
CN (3) | CN106986784A (ja) |
AU (1) | AU2010320832B2 (ja) |
BR (1) | BR112012012358B8 (ja) |
CA (1) | CA2781718C (ja) |
CY (1) | CY1114342T1 (ja) |
DK (1) | DK2503990T3 (ja) |
ES (1) | ES2426271T3 (ja) |
HR (1) | HRP20130773T1 (ja) |
IL (1) | IL219928A (ja) |
MX (1) | MX2012005939A (ja) |
NZ (1) | NZ600334A (ja) |
PL (1) | PL2503990T3 (ja) |
PT (1) | PT2503990E (ja) |
RS (1) | RS52915B (ja) |
RU (1) | RU2539576C2 (ja) |
SI (1) | SI2503990T1 (ja) |
WO (1) | WO2011061341A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2977369A1 (en) * | 2014-07-24 | 2016-01-27 | Bracco Imaging SPA | Preparation of a solid form of gadobenate dimeglumine |
CN106053642A (zh) * | 2016-05-27 | 2016-10-26 | 扬子江药业集团广州海瑞药业有限公司 | 一种钆贝葡胺的含量检测控制方法 |
CN111375070A (zh) * | 2018-12-26 | 2020-07-07 | 江苏恒瑞医药股份有限公司 | 一种制备造影剂的方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1213029B (it) | 1986-01-30 | 1989-12-07 | Bracco Ind Chimica Spa | Chelati di ioni metallici paramagnetici. |
AU620841B2 (en) | 1987-12-24 | 1992-02-27 | Bracco International B.V. | Macrocyclic chelating agents and chelates thereof |
DE4009119A1 (de) * | 1990-03-19 | 1991-09-26 | Schering Ag | 1,4,7,10-tetraazacyclododecan-butyltriole, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel |
DE4237943C2 (de) * | 1992-11-06 | 1997-10-23 | Schering Ag | Verfahren zur Herstellung von Metallkomplexen der N-beta-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,7,10-tetraazacyclododecan- und N-beta-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivate |
JPH06181890A (ja) * | 1992-10-06 | 1994-07-05 | Terumo Corp | Mri造影剤 |
JPH10509424A (ja) * | 1994-10-03 | 1998-09-14 | ザ トラスティーズ オブ ザ ユニバーシティー オブ ペンシルバニア | 磁気共鳴イメージングで顕著な効果を示すキレート錯体 |
DE19958586A1 (de) * | 1999-12-06 | 2001-06-07 | Aventis Res & Tech Gmbh & Co | Mikropartikel auf Basis von Asparaginsäure und deren Verwendung als MRI-Kontrastmittel |
GB0123013D0 (en) * | 2001-09-25 | 2001-11-14 | Upperton Ltd | Improvements relating to imaging contrast agents |
EP1762563A1 (en) * | 2005-09-13 | 2007-03-14 | BRACCO IMAGING S.p.A. | Process for the preparation of contrast agents |
US8192721B2 (en) * | 2007-12-13 | 2012-06-05 | Verrow Pharmaceuticals, Inc. | Compositions useful for reducing toxicity associated with gadolinium-based contrast agents |
-
2009
- 2009-11-23 EP EP09176713A patent/EP2327395A1/en not_active Withdrawn
-
2010
- 2010-11-23 AU AU2010320832A patent/AU2010320832B2/en active Active
- 2010-11-23 CN CN201710218840.9A patent/CN106986784A/zh active Pending
- 2010-11-23 CN CN202110457242.3A patent/CN113105346A/zh active Pending
- 2010-11-23 CA CA2781718A patent/CA2781718C/en active Active
- 2010-11-23 DK DK10781898.1T patent/DK2503990T3/da active
- 2010-11-23 US US13/510,409 patent/US20120232151A1/en not_active Abandoned
- 2010-11-23 PL PL10781898T patent/PL2503990T3/pl unknown
- 2010-11-23 RU RU2012125964/04A patent/RU2539576C2/ru active
- 2010-11-23 KR KR1020127015988A patent/KR101624504B1/ko active IP Right Grant
- 2010-11-23 RS RS20130346A patent/RS52915B/en unknown
- 2010-11-23 SI SI201030311T patent/SI2503990T1/sl unknown
- 2010-11-23 ES ES10781898T patent/ES2426271T3/es active Active
- 2010-11-23 CN CN2010800595178A patent/CN102724964A/zh active Pending
- 2010-11-23 NZ NZ600334A patent/NZ600334A/en not_active IP Right Cessation
- 2010-11-23 BR BR112012012358A patent/BR112012012358B8/pt active IP Right Grant
- 2010-11-23 WO PCT/EP2010/067981 patent/WO2011061341A1/en active Application Filing
- 2010-11-23 PT PT107818981T patent/PT2503990E/pt unknown
- 2010-11-23 JP JP2012539358A patent/JP5607746B2/ja active Active
- 2010-11-23 MX MX2012005939A patent/MX2012005939A/es active IP Right Grant
- 2010-11-23 EP EP10781898.1A patent/EP2503990B1/en active Active
- 2010-11-23 KR KR1020167008973A patent/KR20160043137A/ko not_active Application Discontinuation
-
2012
- 2012-05-22 IL IL219928A patent/IL219928A/en active IP Right Grant
-
2013
- 2013-08-02 CY CY20131100662T patent/CY1114342T1/el unknown
- 2013-08-16 HR HRP20130773AT patent/HRP20130773T1/hr unknown
-
2016
- 2016-04-15 US US15/130,160 patent/US9795695B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2228148T3 (es) | Metodo de produccion de particulas de farmacos. | |
US20130172271A1 (en) | Pharmaceutical Spray Drying | |
JP5607746B2 (ja) | 固体のガドベネートジメグルミン錯体の製造方法 | |
KR102262743B1 (ko) | 주사용 조성물 | |
JP7226859B2 (ja) | トラセミドリン酸エステルプロドラッグ、その調製方法及び組成物 | |
US9511341B2 (en) | Method for preparing acetazolamide sodium powder | |
CN111233684B (zh) | 钆贝葡胺的固体形式的制备 | |
WO2017040362A1 (en) | Process for preparing spray dried solid dispersions of (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide for pharmaceutical preparations | |
CA1252103A (en) | Crystalline gluconate salt of 4'-(9-acridinylamino)- methanesulfo-m-anisidide | |
WO2019151133A1 (ja) | ボルテゾミブ結晶の製造方法 | |
US20080096970A1 (en) | Stable Nateglinide Form B Compositions | |
JPS5817728B2 (ja) | アンピシリンナトリウムエン ノ セイホウ | |
KR19990064341A (ko) | N-(4-옥소-2-(1h-테트라졸-5-일)-4h-1-벤조피란-8-일)-4-(4-페닐부톡시)벤즈아미드의 염 | |
CN104910136A (zh) | 一种采用粒子过程晶体产品分子组装与形态优化技术制备的泮托拉唑钠化合物及其制剂 | |
SK14362001A3 (sk) | Spôsob prípravy benzatín fenoxymetylpenicilínu |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130919 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131001 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131219 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131227 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140327 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140422 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140707 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140805 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140828 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5607746 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |